Thalassaemia major has long been a cause of concern in Azerbaijan. 3 The prevalence of thalassaemia trait ranges from 0 to 20% in relation to altitude: in the capital Baku, which contains 30% of the total population, it is 6 to 8%.4 Hb S is also present,5 and Hb E has been reported. The birth rate of children with thalassaemia major is thought to be about 1/1000, and over 200 affected births are expected annually. In short, the problem seems to be similar to that in Greece. 6 In Baku at least 60 affected births are expected annually. The Children's Hospital provides a thalassaemia service, and a day transfusion unit has recently been established at the Institute of Haematology.
Published evidence suggests that a relatively mild form of thalassaemia may be common in Azerbaijan. Only half of 82 patients described by Akhundova3 were transfusion dependent, and 18 had laboratory and clinical findings similar to those in patients homozygous for the mild "Portuguese" (IVS1-6) 3 thalassaemia mutation.7 "Silent" carriers with a normal Hb A2 level have been reported,4 and globin biosynthesis studies have shown unusually high (30%) Hb A production in some patients. 8 In addition, it has been said that many patients are "cured" by splenectomy (G Abdullaev, personal communication). If the common type of thalassaemia is mild, recommendations for treatment and indications for prenatal diagnosis might differ from those in other areas.
We have studied the clinical picture of thalassaemia and the frequency and types of the associated 3 thalassaemia mutations in Azerbaijan. The usual form of thalassaemia is severe; there is a wide variety of thalassaemia mutations but only four are really common. Only a minority of affected births are associated with parental consanguinity. The findings indicate the need for a thalassaemia control programme6 and provide a foundation for patient management, population screening, genetic counselling, and prenatal diagnosis.
Population and methods Between 1989 and 1992, 120 thalassaemic patients in 99 families were examined at the Children's Hospital in Baku or at the Genetics Unit of the Institute of Obstetrics or both. The sample of patients seen is thought to be representative, as no other centres provide services for thalassaemia. A history was taken verbally and from the notes, patients were assessed clinically, and recommendations were made for future management.9 Parental consanguinity was noted.
Haematological indices were measured using a Coulter CBC5 particle size analyser.
Hb A2 estimations were made by the column method. Blood samples from 13 children (eight with ,B thalassaemia major, five with thalassaemia intermedia) were labelled for globin biosynthesis studies, which were per- 
three affected children, one had very mild and two had severe thalassaemia intermedia. In two of these three families, one parent and the less severely affected child were both reported to have Hb H on electrophoresis, as well as typical findings of P thalassaemia trait or 1 thalassaemia major. The parents were closely related (mostly first cousins) in 28 of the 99 families studied.
CLINICAL PICTURES
The two children with Hb H disease had severe problems. One was a 12 year old girl, previously quite well, who now had a spleen palpable 10 cm and Hb 6-4 g/dl: she has since undergone splenectomy. The second was a child of 6 years old with a spleen enlarged 8 cm, who has been transfusion dependent since 3 months of age.
Patients with thalassaemia major were managed on a low transfusion scheme (mean pretransfusion Hb 6 to 65 g/dl: mean Hb maintained by transfusion varied from 7 to 95 g/dl). Most had a typical thalassaemic appearance and most over 3 to 4 years old had a large spleen and some growth retardation. Splenectomy, hitherto rarely done for fear of overwhelming infection, was recommended for 27 patients with a spleen palpable more than 6 cm and a blood consumption over twice that expected.9 Regular iron chelation therapy is not available, but some families obtain desferrioxamine at the time of transfusion, or for intramuscular injection twice a week.
LABORATORY RESULTS
Thirty of the 32 blood samples from parents of children with homozygous 1 thalassaemia examined showed typical microcytosis and an Hb A2 above 3 5%. However, in two cases the Hb A2 was 3-4% (borderline). DNA studies showed a typical°1 thalassaemia gene (codon 8-AA) in both cases. One was a very anaemic woman (Hb 8-2 g/dl), and the other had an MCH of 26 pg, suggesting coincidental a thalassaemia. '8 Globin biosynthesis studies showed P+ thalassaemia in two of five children with severe thalassaemia major and in three of eight patients with definite or possible thalassaemia intermedia. The remainder had P1 thalassaemia. The "Turkish" [B°mutation (codon 8-AA), the Mediterranean ,B°mutation IVS2-1 (G-÷A), and the Mediterranean P[ mutation IVSl-l 0 (G-+A) accounted for two thirds of all mutations. In patients under 10 years old, they accounted for 82% of mutations. Codon 8-AA was the commonest mutation found in patients with thalassaemia major. IVS2-1 was equally associated with thalassaemia major and thalassaemia intermedia. It was the commonest mutation found in patients with thalassaemia intermedia though, as in other studies, many different mutations including mild P[ mutations like IVS1-6 (T-.C) and -88 (C-+A) were also found in these patients. The severe codon 8-AA mutation did occur in three patients with thalassaemia intermedia (one was even homozygous), but in two of these families there was evidence of an independent moderating factor (probably coincidental a thalassaemia), as a sib had more severe disease.
In 24 of the 38 families with DNA studies the parents carried different mutations. Both parents carried the same mutation in 6/10 families where the parents were consanguineous, and in 8/28 where they were not.
Discussion
Until recently in Azerbaijan most thalassaemic children died very young. However, in recent years infant mortality has dropped and diagnosis and treatment are becoming available. Consequently patient numbers are rising, and thalassaemia is emerging as a public health problem comparable, for example, to that in Greece. There (in the absence of prevention) 150 to 200 affected births would occur annually in a population of 10 million6: in Azerbaijan over 200 affected births are expected annually in a population of 6-5 million.
Earlier observations suggested that a mild form of P thalassaemia is common in Azerbaijan, but we have found that the disease is as severe as elsewhere. High mortality among young children with thalassaemia major leading to selective survival of patients with thalassaemia intermedia accounts for the earlier findings. It also explains the observation that many patients are "cured" by splenectomy. [3 thalassaemia genes in the population.
A thalassaemia control programme including improved patient care, a patients' and parents' support group, and information, screening, genetic counselling, and prenatal diagnosis is planned on the basis of established models in the Mediterranean area.2' Prevention is particularly important in Azerbaijan because adequate transfusion can be provided (in principle), but the iron chelation therapy needed for long term survival cannot. A programme of carrier screening and counselling, and the offer of DNA based prenatal diagnosis to carrier couples is planned. Carrier couples will be tested for the three mutations (codon 8-AA, IVS2-1, and IVS1-1 10) which account for over 80% of [ thalassaemia mutations in young patients. If these are not found the rarer mutations will be sought, or RFLP linkage studies will be used.
To provide a sound basis for genetic counselling, it is also desirable to assess the severity of the different [ 
